# Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia

> **NCT06802718** · PHASE3 · RECRUITING · sponsor: **Peking University People's Hospital** · enrollment: 96 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Interferon

## Key facts

- **NCT ID:** NCT06802718
- **Lead sponsor:** Peking University People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-01-01
- **Primary completion:** 2026-12
- **Final completion:** 2026-12
- **Target enrollment:** 96 (ESTIMATED)
- **Last updated:** 2025-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06802718

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06802718, "Interferon-alpha As Maintenance Therapy for Favorable-risk Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT06802718. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*